Metformin, Empagliflozin With Sitagliptin vs Linagliptin in Type 2 Diabetes

A phase 4 trial registered on ClinicalTrials.gov. The registry status is enrolling by invitation. It plans to enroll 110 participants.

Also called NCT07452913

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 110 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07452913
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Pakistan (from the registry)
Registry status
  • Enrolling by invitation (from the registry)

Technical summary

Registry record NCT07452913. Randomized; no masking; primary purpose treatment. Start 2026-01-01 (actual); primary completion 2026-03-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Metformin, Empagliflozin With Sitagliptin vs Linagliptin in Type 2 Diabetes
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Metformin+ Empagliflozin + Sitagliptin
Intervention (Drug)
Metformin + Empagliflozin + Linagliptin
Lead sponsor
Bahria University (class: other)

Record details

Record id
cardio:ct-nct07452913
Content hash
e11ff5df1aba33390dab5c9a2101f83173c4a3271e935454c29ba8cc09f0e4b3